)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
SynAct Pharma
SynAct Pharma (SYNACT) investor relations material
SynAct Pharma Aktiedagarna 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Aktiedagarna 2026 summary10 Jun, 2026
Strategic focus and therapeutic approach
Shifted focus to developing pro-resolution therapies for immune system diseases, targeting both chronic and acute inflammatory conditions.
Pro-resolution immunology aims to modulate immune cells without immunosuppression, potentially reducing side effects compared to current treatments.
Lead compound, resomelagon (AP1189), is a once-daily oral therapy with a novel, non-immunosuppressive mechanism.
Clinical development and pipeline
Lead program is in phase II-B for rheumatoid arthritis, with top-line data expected in June.
Pipeline includes additional trials in respiratory viral infections and dengue, leveraging the broad applicability of the mechanism.
Animal models and ongoing clinical programs support potential efficacy across multiple indications.
Market opportunity and positioning
Addressing a large market, with rheumatoid arthritis and related indications representing a $26–30 billion opportunity.
Targeting patients who do not respond to first-line therapies, aiming to delay or avoid progression to expensive biologics.
Non-immunosuppressive profile could allow earlier intervention and improved safety.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SynAct Pharma
- ADVANCE Phase 2b RA study completed dosing; cash runway extended after SEK 51.9M share issue.SYNACT
Q1 202627 May 2026 - Upcoming clinical data and strong financials position the pipeline for major partnering deals.SYNACTCMD 202611 Mar 2026
- R&D-driven losses deepened in 2025, but major clinical milestones set up a transformative 2026.SYNACTQ4 202518 Feb 2026
- ADVANCE Phase 2b study for resomelagon in high-activity RA targets data and deals by 2025.SYNACTCMD 202420 Jan 2026
- Phase IIB results for a novel immune-modulating therapy in RA and viral infections expected next year.SYNACTLife Science Summit 202524 Dec 2025
- RA Phase 2B data expected year-end; pipeline expanded, funding secured through 2026.SYNACTCMD 202519 Nov 2025
- Losses widened on higher R&D, but financing extended cash runway into 2027.SYNACTQ3 202530 Oct 2025
- ADVANCE Phase 2b RA study progresses, financial runway extended into 2027 via new funding.SYNACTQ2 202520 Aug 2025
- ADVANCE Phase 2b study launched; liquidity shortfall requires new capital for continued operations.SYNACTQ3 202413 Jun 2025
Next SynAct Pharma earnings date
Q2 202620 Aug, 2026
SynAct Pharma
Next SynAct Pharma earnings date
Q2 202620 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage